SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is experiencing significant downward volatility, which many traders are attributing to market manipulation and an aggressive sell-off despite what they view as strong recent earnings. Some participants express concern over potential regulatory headwinds or the broader rotation of funds into other sectors, while others maintain a bullish long-term outlook and are viewing the price decline as an opportunity to add to their positions.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD shares are trending higher following an optimistic long-term growth outlook presented at a recent industry conference, where the company raised its addressable market projections for 2030 and signaled confidence in strong AI data center demand. While bulls celebrate the recovery and positive AI infrastructure narrative, some traders express skepticism regarding the company's valuation and the broader sustainability of the current AI-sector rally.

ServiceTitan, Inc. engages in the collection of field service activities required to install, maintain, and service the infrastructure and systems of residences and commercial buildings. The company was founded by Ara Mahdessian and Vahe Kuzoyan on June 8, 2008 and is headquartered in Glendale, CA.

ServiceTitan Inc. - Ordinary Shares - Class A

ServiceTitan 

ServiceTitan shares plummeted following the company's fiscal second-quarter earnings report, where a revenue guidance miss for the third quarter and the resignation of its Chief Revenue Officer overshadowed a top- and bottom-line beat. The community reaction is highly polarized, with many traders viewing the double-digit percentage decline as an excessive overreaction while others caution against potential further downside.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as traders react to a sharp price decline and debates regarding the company's heavy AI infrastructure spending and capital expenditure. The community remains divided, with some viewing the pullback as a buying opportunity for a long-term position, while others express frustration over the stock's recent price action and skepticism about its short-term recovery.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending due to Google's massive infrastructure investment in Finland, which involves Nokia providing connectivity for new data center sites, alongside positive sentiment regarding the company's upcoming return to the Euro Stoxx 50 index. Traders are expressing bullish optimism that these catalysts, combined with Nokia's strategic pivot toward AI-driven networking and optical technology, support a potential re-rating for the stock.

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Opus Genetics Inc.

Opus Genetics is trending following the release of positive topline results from its Phase 3 clinical trial for phentolamine ophthalmic solution in treating presbyopia. The community is debating the stock's price action, with some investors optimistic about future catalysts and institutional interest, while others express frustration over intraday volatility and management-related concerns.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Compass Pathways is trending as investors anticipate upcoming catalysts, including the company's Q2 earnings, progress toward a Q4 2026 NDA submission, and the potential for a 2027 commercial launch. Community discussion remains largely bullish, focusing on recent clinical trial results and the company's partnership with the U.S. Department of Veterans Affairs, while debating the stock's valuation relative to its industry peers.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is seeing increased attention following a large insider stock purchase by director Lawrence Cheng after the company reported quarterly results. While some traders are expressing frustration over stagnant price action and a lack of official earnings calls, others remain bullish on the long-term outlook, citing the company's strong cash position and potential for future strategic moves.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple shares are trending as traders debate the potential market impact of the upcoming iPhone launch event, specifically regarding the rumored foldable model and the first keynote by new CEO John Ternus. Sentiment is mixed, with participants weighing the risk of a "sell the news" decline against hopes for a rally driven by product innovation and potential buybacks.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores is trending after reporting fiscal first-quarter results that beat analyst expectations on both earnings and revenue. However, the stock price declined as investors expressed concern over slower same-store sales growth and the company's decision to leave its full-year guidance unchanged.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CMPS Stock Defies Market Selloff After Compass Pathways Psilocybin Trial Success Pointing To 2027 Launch

CMPS Stock Rallies On Launch-Prep Push Ahead Of FDA Psychedelics Hearing

The price move is being attributed to Compass Pathways' launch of a U.S. doctor education campaign and upcoming conference presentations, which investors view as progress toward a potential FDA submission. Sentiment was further bolstered by anticipation for an upcoming FDA public hearing regarding the therapeutic use of psychedelic drugs.

Equity

Compass said patients who received an additional 25 mg dose of COMP360 saw their depression scores improve by an average of 13 points after 52 weeks.

Compass Pathways New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the topline 52-week results (Part C) from its Phase 3 COMP005 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for...

CMPS Stock Rallies On Launch-Prep Push Ahead Of FDA Psychedelics Hearing  

Compass has said a rolling FDA application is already underway for its COMP360, with the package due to be completed in the fourth quarter of 2026 and a possible U.S. launch in the first half of 2027. 


Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at Psych Congress 2026, taking place in New Orleans, LA, from September 14-19. The Company will debut Change the Tune in...

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirty-one newly hired non-executive employees...

Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree

Compass Pathways, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, has been named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech and Fierce Healthcare. The Fierce 50 recognizes 50 individuals and organizations...

Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and will participate in a fireside chat at...

CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics

The most closely watched next step for Compass is the completion of its application to the U.S. Food and Drug Administration for COMP360, its synthetic psilocybin treatment aimed at people with depression that has not responded to other options.

COMPASS Pathways (CMPS) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, and will participate in a fireside...

Extremely Bullish Sentiment

$CMPS

$SOUN

$MRNA

$LCID

Compass Pathways ($CMPS), SoundHoundAI ($SOUN), Moderna ($MRNA), and Lucid Group ($LCID) are four of the most searched and talked-about stocks among retail investors this morning. Which are you most bullish? Drop your reasoning in the comments.

Which of these trending stocks are you most bullish on for the next 5 years - $CMPS, $SOUN, $MRNA, or $LCID?

Stocktwits

SoundHound AI Inc

Moderna Inc

Lucid Group Inc

Which of these trending stocks are you most bullish on for the next 5 years - 

Stocktwits Polls

Traders are closely monitoring the key 15 dollar resistance level as a potential breakout point for major momentum.

Investors are preparing for the upcoming rolling NDA submission in Q4 2026, marking a critical step toward potential FDA approval.

Rising sector interest surrounding upcoming conference presentations and federal preparations for potential clinical psychedelic therapy launches.

Speculation of a potential bidding war or acquisition remains high as big pharma looks to secure a foothold in the growing sector.

Recent 52-week data updates show promising and sustained patient outcomes, fueling bullish sentiment on long-term treatment efficacy.

Current Price	$14.96
Prev Close	$14.04
Open	$14.27
Dividend Yield	0.00%
50-Day Moving Average	$13.10
Beta	1.43
Avg. Volume	2.69M
PE Ratio	-3.04

52-Week High	$15.40
52-Week Low	$4.82
Market Capitalization	$1.94B
EPS (Annual)	-$3.09
Price to Book	22.54
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CMPS Fundamentals